Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA In Danger From Lack Of Resources, Says Commissioner Von Eschenbach

This article was originally published in The Gray Sheet

Executive Summary

Rapid technological developments in an increasingly complex environment require an FDA that is "stronger, bigger and better," and the agency's current resources cannot keep up with that demand, says FDA Commissioner Andrew von Eschenbach

You may also be interested in...



Senate Budget Bill Responds To Outcry, Adds $375 Million To FDA

Recent calls to significantly increase FDA funding are starting to yield fruit, evidenced by Senate passage March 14 of $375 million in additional funds for the agency as part of the FY 2009 budget package for the U.S. government

McClellan Tapped To Chair Controversial Reagan-Udall Foundation

Former CMS administrator and FDA commissioner Mark McClellan has been tasked by the Bush administration to lead and lend his good name to the Reagan-Udall Foundation, a federally established nonprofit organization that has yet to have bylaws, but has already come under attack for increasing the window for industry influence on FDA

FDA Hears Experience Of Regional Device Safety Registries

FDA is soliciting ideas from regional programs that gather postmarket data to help design its proposed "Sentinel Network" for medical product safety information

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel